Janssen’s Brian Woodfall discusses the pharmaceutical company’s research process for their monthly injectable HIV treatment and their predictions for the future of the condition.

Learn how to evaluate the fitness of a TOC instrument based on USP <1058> and ICH Q2(R1).

A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.

A Biologics License Application and priority review has been approved by the FDA for an investigational Ebola vaccine.

Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.